- Home
- PHT vs GOSS Comparison
PHT vs GOSS Comparison
Compare PHT & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- GOSS
- Stock Information
- Founded
- PHT 2002
- GOSS 2015
- Country
- PHT United States
- GOSS United States
- Employees
- PHT N/A
- GOSS N/A
- Industry
- PHT Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- PHT Finance
- GOSS Health Care
- Exchange
- PHT Nasdaq
- GOSS Nasdaq
- Market Cap
- PHT 231.2M
- GOSS 203.3M
- IPO Year
- PHT N/A
- GOSS 2019
- Fundamental
- Price
- PHT $8.00
- GOSS $1.26
- Analyst Decision
- PHT
- GOSS Strong Buy
- Analyst Count
- PHT 0
- GOSS 4
- Target Price
- PHT N/A
- GOSS $7.75
- AVG Volume (30 Days)
- PHT 85.5K
- GOSS 1.4M
- Earning Date
- PHT 01-01-0001
- GOSS 05-15-2025
- Dividend Yield
- PHT 8.76%
- GOSS N/A
- EPS Growth
- PHT N/A
- GOSS N/A
- EPS
- PHT 0.98
- GOSS N/A
- Revenue
- PHT N/A
- GOSS $124,590,000.00
- Revenue This Year
- PHT N/A
- GOSS N/A
- Revenue Next Year
- PHT N/A
- GOSS $190.37
- P/E Ratio
- PHT $7.71
- GOSS N/A
- Revenue Growth
- PHT N/A
- GOSS N/A
- 52 Week Low
- PHT $6.41
- GOSS $0.50
- 52 Week High
- PHT $7.60
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- PHT 67.19
- GOSS 62.39
- Support Level
- PHT $7.89
- GOSS $1.09
- Resistance Level
- PHT $7.96
- GOSS $1.29
- Average True Range (ATR)
- PHT 0.08
- GOSS 0.09
- MACD
- PHT -0.00
- GOSS 0.01
- Stochastic Oscillator
- PHT 93.10
- GOSS 88.46
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.